Skip to main content
ADIA
OTC Life Sciences

Adia Med Q3 10-Q: Going Concern Warning Persists Despite Revenue Nearly Doubling

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.128
Mkt Cap
$12.084M
52W Low
$0.023
52W High
$0.278
52W Position info
469% above low
Off High info
54% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ADIA has more than doubled off its 52-week low of $0.023 on light trading volume (0.2× avg).

Summary

Adia Med's Q3 2026 10-Q shows revenue nearly doubling to $1.02M for nine months, but a $271,922 net loss, a $16.2M accumulated deficit and a reiterated going concern warning, plus disclosure controls deemed not effective.


Key Events · Earnings and Guidance · ADIA

  • Going Concern Doubt Reiterated

    Management states the $16,245,404 accumulated deficit and $128,369 working capital raise substantial doubt about continuing as a going concern for a reasonable period.

  • Revenue Nearly Doubles, Loss Persists

    Nine-month revenue rose to $1,019,245 from $521,958, but the company posted a $271,922 net loss and used $239,653 of cash in operations.

  • Disclosure Controls Not Effective

    The CEO and CFO concluded disclosure controls and procedures were not effective as of September 30, 2026.

  • Q2 2026 Figures Revised Downward

    An immaterial error in IRB study revenue recognition cut $96,800 from previously reported revenue and net income for the three and six months ended June 30, 2026.


Analysis · ADIA · Life Sciences

Revenue for the first nine months of 2026 nearly doubled to $1,019,245 from $521,958, yet the company still lost $271,922 and carries a $16,245,404 accumulated deficit with only $128,369 of working capital. Management explicitly states these factors raise substantial doubt about the ability to continue as a going concern, and disclosure controls were concluded not effective. The cash balance of $1,137,818 looks healthier only because of the $1,000,000 cash received from selling 30% of Adia Labs; operations themselves burned $239,653. The company also revised its Q2 2026 figures, cutting $96,800 of previously reported revenue and net income. For a nano-cap trading near $0.13, the going concern language and ineffective controls are the dominant facts.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIA was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.02 to $0.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIA - Latest Insights

ADIA
Oct 19, 2026, 11:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.130
Real-time Price: $0.128 info
Change: -$0.0020 (-2%) info
Market Cap: $12.084M info
ADIA
Oct 05, 2026, 7:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.101
Real-time Price: $0.128 info
Change: +$0.027 (+27%) info
Market Cap: $12.084M info
ADIA
Oct 05, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.101
Real-time Price: $0.128 info
Change: +$0.027 (+27%) info
Market Cap: $12.084M info
ADIA
Aug 13, 2026, 11:28 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1195
Real-time Price: $0.128 info
Change: +$0.0085 (+7%) info
Market Cap: $12.084M info
ADIA
May 26, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.160
Real-time Price: $0.128 info
Change: -$0.032 (-20%) info
Market Cap: $12.084M info